How the study estimated weight-management eligibility
Researchers applied the Therapeutic Goods Administration’s approved indications to data from 13,039 Australian adults. The chronic weight-management indication uses an initial BMI of at least 30, or a BMI of at least 27 but below 30 with at least one weight-related condition. The weighted estimate was 39.7% (95% confidence interval, 38.4% to 41.0%), or 7.8 million adults (7.6 million to 8.1 million). An estimated 2.9 million met the criteria without a weight-related comorbidity.[1][2]
Australian subsidy decisions use separate criteria. The guide to U.S. Wegovy coverage illustrates how an approved indication can be relevant to a coverage decision under a different system. For a U.S. example, the Form Health review describes the clinic’s separate enrollment criteria. The Australian survey estimated how many adults matched its regulator’s indications. It did not measure who received a prescription or a subsidy.[1]
Why the cardiovascular estimate is an upper bound
Australia’s Wegovy indication for cardiovascular risk reduction requires established cardiovascular disease, a BMI of at least 27, and no established type 1 or type 2 diabetes. The researchers estimated that 285,700 adults met their definition of confirmed established disease. Including 53,200 adults who met their broader definition of possible established disease gave an upper estimate of 338,900 (95% confidence interval, 271,300 to 406,500).[1][2]
The 2022 survey used directly measured height and weight when available. About 40.8% of respondents lacked measured BMI. For those respondents, the Australian Bureau of Statistics estimated height and weight using reported values and other variables. The survey could not reliably identify some contraindications or verify every cardiovascular diagnosis.[1]
What changed after the study
Australia registered Wegovy tablets on November 3, 2026, for chronic weight management and cardiovascular risk reduction in adults. The TGA’s November assessment lists the same adult eligibility thresholds for the injection and the tablet. The registration does not change the 2022 survey population used for the estimates.[2]